...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The oncologist >A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups
【24h】

A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups

机译：寡核瘤卵巢癌（MITO RT1研究中立体定向体放射疗法（SBRT）的疗效和安全性的大型多中心，复述研究：MITO，AIRO GYN和MANGO组的合作

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC). Materials and Methods The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on “per-lesion” basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes. Results CR, PR, and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of 96.4%. Patient aged ≤60?years, planning target volume (PTV) ≤18 cm 3 , lymph node disease, and biologically effective dose α/β10 ?70 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range, 3–120), the 24-month actuarial LC rate was 81.9%. Achievement of CR and total dose 25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7%) patients; of 63 side effects, 48 were grade 1, and 15 were grade 2. The 24-month late toxicity-free survival rate was 95.1%. Conclusions This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate. Implications for Practice This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age 70 Gy were associated with higher chance of complete response (CR). Achievement of CR and total dose 25 Gy were associated with better local control (LC) rate. Mild toxicity was experienced in 20.7% of patients. In conclusion, this study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.
机译：背景技术最近的研究报告了在非小细胞肺癌和前列腺癌中具有立体定向体放射治疗（SBRT）的改善了改善了结果（无进展生存，整体存活率和雄激素剥夺治疗的延长）。这种回顾性的多中心研究（MITO RT-01）的目的是定义SBRT的活性和安全性，在一个非常大的现实世界数据集的转移性，持续和复发性卵巢癌（MPR-OC）中。材料和方法该研究的终点是完全反应（Cr）到SBRT的速率和24个月的致算局部控制（LC）率为“每次病变”的基础。次要终点是急性和晚期毒性和24个月的致剂晚期毒性存活。客观响应率（ORR）包括CR和部分响应（PR）。临床益处（CB）包括ORR和稳定的疾病（SD）。根据中心政策，通过放射治疗肿瘤学群（RTOG）和欧洲研究和治疗癌症（EORTC）和常见术语标准的癌症（CTCAE）级别的常见术语标准评估毒性。物流和Cox回归用于预测临床CR和精算结果的因素的单相和多变量分析。结果在291（65.2％），106（23.8％）和33（7.4％）病变中观察到效果Cr，Pr和Sd，率为96.4％的速率。患者≤60？岁月，规划靶体积（PTV）≤18cm3，淋巴结疾病，以及生物有效剂量α/β10＆Δ70GY与多变量分析中Cr的较高机会相关。 22个月（范围3-120）中位随访，24个月的精算LC率为81.9％。实现Cr和总剂量＆ 25 gy与多变量分析中的更好的LC速率相关。 54名（20.7％）患者体验轻度毒性; 63副作用，48分为1级，15级为2级。24个月的晚期毒性生存率为95.1％。结论本研究证实了MPR-OC患者的SBRT的活性和安全性，并识别能够预测CR和LC率的临床和治疗参数。对实践的影响本研究旨在在长大的现实生活数据集（MPR-OC）的患者中，定义立体定向体放射治疗（SBRT）的活性和安全性。患者年龄70 GY与更高的完全反应（CR）有关。 CR和总剂量＆GT的成就与更好的局部控制（LC）率相关。 20.7％的患者体验轻度毒性。总之，本研究证实了MPR-OC患者中SBRT的活性和安全性，并鉴定了能够预测CR和LC率的临床和治疗参数。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号